It seems uneducated sellers through the baby out with the bath water on this one. The secondary came at the same time all biotechs were slammed by Hillary fear. Low float + biotech plunge = bargain prices for CXRX.
S&P Revises Concordia Healthcare Outlk To Pos; Rtgs Afrmd
Concordia coverage resumed with an Outperform at RBC Capital
RBC Capital resume coverage on Concordia with an Outpeform rating and an $86 price target on shares. The firm believes the exceptional recent weakness in Concordia shares is unwarranted and as such would be aggressive buyers and notes the pending AMCo acquisition, diversifies its global revenue base further away from the U.S.
Sentiment: Strong Buy
Wow this is stunning fall after the $65 announcement. I think this is a case of the throwing out the baby and the bath water. This us unfairly being caught up in the overall biotech panic caused by Hillary Clinton's comments.
CXRX is actually making money. And they announced the $65 secondary, which should have been the floor instead of new resistance.
No doubt the low float is contributing to this 2 day plunge. Also Friday's buyers are todays sellers.
Sientra U.S. supply should not be impacted from halt, says Piper Jaffray.
This is such a low float stock at 5M, it is easily moved by good or bad news.
there is no market stops on a huge rise in the morning. My experience is that if there are not shares to short for a stock when good news comes out, there is nothing to stop an influx of buyers.
JPMorgan analyst Sterling Auty attributes today's pullback in shares of Synchronoss Technologies (SNCR) to a research note from Baird talking about the potential loss of Verizon (VZ) as a cloud customer. The comments come after the wireless carrier changed the pricing in the Verizon cloud offering. Auty sees "no chance" of Synchronoss losing Verizon as a customer in the near-term since the wireless carrier recently renewed its contract with the company for multiple years. He views today's selloff as a "significant overreaction" and recommends buying Synchronoss at current levels. Shares are off their lows but remain down $5.91 to $31.48 in morning trading
Shorts are controlling this now. It is easy to manipulate a low float stock.
Some capitulation has just occured taking this ZUMZ just under $15
Doubtful it will get back to 18 given magnitude of loss. Any nearterm pops will be sold as day traders licking their wounds and clearing their position.
Having said that 29 million is a low float and ZUMZ usually trades only 400k/day. So the combination could result in a quick rise to offset some of the plunge.
wow, is this ever a bargain now. I am not a shopper of Zumiez, but whenever I pass it in the mall it is busy.
The current PPS has dropped the forward earnings to 9.56 and PEG to 1.21. The PE is below a reasonable level now and implies that even though they missed earnings, the PPS has become an attractive entry point now.
43% of CHKE's paltry revenue came from Target. The president selling 10000 shares in June was a warning.
I suspect Wunderlich's review was prior to Target dropping CHKE, since Wunderlich's announcment does not even mention CHKE losing Targe and 43% of its business.
Could easily plunge under $10
Avg Vol (3 month)3: 4,144,630
Avg Vol (10 day)3: 3,822,730
Shares Outstanding5: 31.34M
% Held by Insiders1: 7.47%
% Held by Institutions1: 33.90%
Shares Short (as of Aug 14, 2015)3: 8.03M
Short Ratio (as of Aug 14, 2015)3: 2.58
Short % of Float (as of Aug 14, 2015)3: 28.74%
Shares Short (prior month)3: 8.34M
People still looking for big beats....Forward PE was 24... AMBA is not trading at a premium at all based on Forwaerd PE. I still like the gross margins....
Ambarella sees Q3 revenue $90M-$93M, consensus $92.33M
Ambarella sees Q3 non-GAAP gross margins 62.5%-64%
Finally the downtrend has been broke. With last week stablizing above $10 and now with today's counter market move, SUNE is poised for a significant short covering rally.
Over 80M shares short...wow! That is a staggering amount.
Not sure how much real potential is here. We'll see how soon the dump after the pump occurs. This morning? or a week from now?
It probably should not have been at $2 a year ago. That was a thinly traded pop. Revenues back then did not justify the price. Now there is some wood behind the arrow and $2 may be realistic after next qtr results.
LOL ... you missed the point. TAPM has moved out of its trading range and is now in a new range. It was not going to go any higher than .60 in the near term.
The move and retrace is all healthy.
Regarding a pump.... it is starting to consistently improve it revenue at a steady clip each qtr. That is not a pump or fabricated. Recent pps was based on latest qtr results. Next move up will rely on future qtr results, which are trending higher.
Another millions already today. TAPM is getting noticed. It needs to stay above .60 for its next move. TAPM has tested .60 twice in last two days.